H
Hangzhou Yingshu Life Technology
A medical device enterprise specialized in the R&D, production and sales of high-end medical endoscope systems
About Hangzhou Yingshu Life Technology
Endoso is a global professional manufacturer specializing in minimally invasive surgical devices. Established in Hunan and later expanding to Shenzhen and Hangzhou, the company operates within the medical device industry, focusing on advanced endoscopy systems. Endoso's core products include 4K ultra high definition fluorescence laparoscopes and thoracoscopes, as well as single-use endoscope solutions. The company serves healthcare providers and medical institutions, offering cutting-edge technology to enhance surgical precision and patient outcomes. Endoso's business model revolves around the development, manufacturing, and distribution of these high-tech medical devices, generating revenue through direct sales and partnerships with medical facilities. The company has achieved significant milestones, including obtaining major certifications such as EU CE, FDA, and NMPA approvals, which validate the quality and safety of its products. Endoso has also gained international recognition by participating in prominent medical exhibitions like the Arab Health and CMEF, showcasing its innovations on the global stage. The company continues to grow, driven by increasing market demand and a commitment to advancing medical technology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- China
- Open positions
- None listed
- Dealroom signal
- 22.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Medical Imaging, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2024 | $14M | $55M | Longpan Investment · Weigao Songyuan Fund | ↗ |
| EARLY VC✓Equity / VC | Nov 2022 | $2.8M | $11M | Vision Plus Capital · BGI Co-Win | ↗ |
Growth signals
Latest recorded traffic for Hangzhou Yingshu Life Technology is 190 monthly website visits, down 64.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Vision Plus Capital
BGI Co-Win- LILongpan Investment
- WFWeigao Songyuan Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Yingshu Life Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Yingshu Life Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.




